Roche helps further reduce risk of severe illness for transplant patients by expanding the portfolio to include Adenovirus Test on the cobas 6800/8800 Systems

-A Immunocompromised transplant recipients are at risk of major complications when infected with adenovirus, a common and highly contagious virus-A Healthcare professionals can use this new test to determine whether transplant patients are at risk of developing severe illness from adenovirus infection-A The Adenovirus Test leverages the flexibility, automation, and reliability of the cobas omni Utility Channel on the cobas 6800/8800 Systems, improving workflow efficiencies compared to laboratory developed testsPLEASANTON, California, Jan. 15, 2020 /PRNewswire/ --A Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the commercial availability of a quantitative Adenovirus (ADV) Test for use with the cobas omni Utility Channel on the cobasA® 6800/8800 Systems in countries accepting the CE mark. The new Adenovirus Test will help healthcare professionals better monitor and manage severely immunocompromised transplant patients at risk of infections. "Transplant patients face the risk of significant complications due to adenovirus and other infections," said Mario Torres, Head of Roche Molecular Diagnostics. "This new addition to our menu provides a more comprehensive solution for laboratories to offer improved monitoring tools so that treatment plans can be adjusted as necessary, providing better patient care."
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2020    »